EGElizabeth Glaser

Elizabeth Glaser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth Glaser has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes of a Program to Support Outpatient Antibiotic Adherence Among People Experiencing Housing Instability With Serious Injection Drug-Related Infections in Boston, MA: A Propensity Score Matched Study

    by Nicole C McCann, Elizabeth Glaser, Jake R Morgan, Dominic Hodgkin, Ghulam Karim Khan, Simeon D Kimmel

    Background: Antibiotics are effective for treating serious injection drug-related infections (SIRIs). However, completion rates are often low among people who inject drugs. We evaluated Boston Healthcare for the Homeless Program Infectious Disease Outreach Liaison Team (BOLT), an outpatient liaison program for people experiencing housing instability hospitalized with SIRI, intended to increase intravenous or oral antibiotic completion. Method: We included BOLT enrollees (1 June 2023 to 31 August 2024) and historical controls (1 June 2020 to 28 February 2023). Primary outcomes were the number of re-hospitalizations and emergency department (ED) visits in the 90-day period following the SIRI index hospitalization. The secondary outcome was probability of patient-directed discharge (PDD) from the index hospitalization. BOLT enrollees and historical controls were matched on demographic and clinical characteristics. In regression analyses, we further adjusted for observed characteristics in a doubly robust approach. Results: Prior to matching, BOLT enrollees and historical controls were significantly different on most characteristics, with BOLT enrollees having higher prevalence of osteomyelitis and epidural abscess SIRIs, and opioid and stimulant use disorders. The matched analytic sample included 74 BOLT enrollees and 121 historical controls. The matching approach achieved balance on most characteristics except osteomyelitis prevalence and methadone receipt. In regression analyses, 90-day re-hospitalization was similar between BOLT enrollees and controls (P = .982). BOLT enrollees had an adjusted mean of 0.35 fewer ED visits per enrollee versus controls over the 90-day postindex hospitalization period (P = .288). Probability of PDD was similar between groups (P = .946). Conclusions: BOLT was not significantly associated with changes in acute health care utilization. This may reflect unobserved differences between BOLT enrollees and historical controls and suggests a need for additional research to understand program implementation and more proximal health outcomes.

  • Open Access

    Quality of life burden on United States infants and caregivers due to lower respiratory tract infection and adjusting for selective testing: Pilot prospective observational study

    by Dhwani Hariharan, V. S. Senthil Kumar, Elizabeth L Glaser, William H. Crown, Zachary A. Wolf, Kimberley A. Fisher, Charles T. Wood, William F. Malcolm, Christopher B. Nelson, Donald S. Shepard

    Background and Aims: Policymakers need data about the burden of respiratory syncytial virus (RSV) lower respiratory tract infections (LRTI) among infants. This study estimates quality of life (QoL) for otherwise healthy term US infants with RSV‐LRTI and their caregivers, previously limited to premature and hospitalized infants, and corrects for selective testing.Methods: The study enrolled infants n = 11) LRTI‐tested infants (66.4) was lower than that in not‐tested LRTI infants (79.6,p = 0.096). For outpatient LRTI infants (n = 23), median QALYs/1000 losses were 9.8 and 0.25 for their caregivers. RSV‐positive outpatient LRTI infants (n = 6) had significantly milder QALYs/1000 losses (7.0) than other LRTI‐tested infants (n = 5)(21.8,p = 0.030). Visits earlier in the year were more likely to be RSV‐positive than later visits (p = 0.023). Modeled RSV‐positivity (51.9%) was lower than the observed rate (55.0%). Infants’ and caregivers’ QALYs/1000 loss were positively correlated (rho = 0.34,p = 0.046), indicating that infants perceived as sicker imposed greater burdens on caregivers.Conclusions: The overall median QALYs/1000 losses for LRTI (9.0) and RSV‐LRTI (5.6) in US infants are substantial, with additional losses for their caregivers (0.25 and 0.20, respectively). These losses extend equally to outpatient episodes. This study is the first reporting QALY losses for infants with LRTI born at term or presenting in nonhospitalized settings, and their caregivers.

  • Open Access

    Determinants of mortality in Postpartum Haemorrhage in Mzimba district, Malawi

    by Monalisa Tembo, Abigail Kazembe, Elizabeth Glaser, Alice Kadango

    Background: Severe Postpartum Haemorrhage (PPH) is one of the major complications following childbirth. Many interventions have helped to reduce its impact on maternal outcomes, nonetheless, it remains one of the major causes of maternal mortality. This study, therefore, aimed to determine the...

  • Open Access

    Impact of Respiratory Syncytial Virus on Child, Caregiver, and Family Quality of Life in the United States: Systematic Literature Review and Analysis

    by Elizabeth L Glaser, Dhwani Hariharan, Diana M Bowser, Raíssa M Gervasio, Katharine R Rowlands, Lauren Buckley, Christopher B Nelson, Donald S Shepard

    Background: Respiratory syncytial virus (RSV), a leading cause of lower respiratory tract infection in US children, reduces quality of life (QOL) of children, their caregivers, and families. Methods: We conducted a systematic literature review in PubMed, EconLit, and other databases in the United States of articles published since 2000, derived utility lost per RSV episode from cohort studies, and performed a systematic analysis. Results: From 2262 unique citations, 35 received full-text review and 7 met the inclusion criteria (2 cohort studies, 4 modeling studies, and 1 synthesis). Pooled data from the 2 cohort studies (both containing only hospitalized premature infants) gave quality-adjusted life-year (QALY) losses per episode of 0.0173 at day 38. From the cohort study that also assessed caregivers' QOL, we calculated net QALYs lost directly attributable to RSV per nonfatal episode from onset to 60 days after onset for the child, caregiver, child-and-caregiver dyad of 0.0169 (167% over prematurity alone), 0.0031, and 0.0200, respectively. Conclusion: Published data on QOL of children in the United States with RSV are scarce and consider only premature hospitalized infants, whereas most RSV episodes occur in children who were born at term and were otherwise healthy. QOL studies are needed beyond hospitalized premature infants.


  • Open Access

    Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis

    by Diana M Bowser, Katharine R Rowlands, Dhwani Hariharan, Raíssa M Gervasio, Lauren Buckley, Yara Halasa-Rappel, Elizabeth L Glaser, Christopher B Nelson, Donald S Shepard

    Background: Limited data are available on the economic costs of respiratory syncytial virus (RSV) infections among infants and young children in the United States. Methods: We performed a systematic literature review of 10 key databases to identify studies published between 1 January 2014 and 2 August 2021 that reported RSV-related costs in US children aged 0–59 months. Costs were extracted and a systematic analysis was performed. Results: Seventeen studies were included. Although an RSV hospitalization (RSVH) of an extremely premature infant costs 5.6 times that of a full-term infant ($10 214), full-term infants accounted for 82% of RSVHs and 70% of RSVH costs. Medicaid-insured infants were 91% more likely than commercially insured infants to be hospitalized for RSV treatment in their first year of life. Medicaid financed 61% of infant RSVHs. Paying 32% less per hospitalization than commercial insurance, Medicaid paid 51% of infant RSVH costs. Infants’ RSV treatment costs $709.6 million annually, representing $187 per overall birth and $227 per publicly funded birth. Conclusions: Public sources pay for more than half of infants’ RSV medical costs, constituting the highest rate of RSVHs and the highest expenditure per birth. Full-term infants are the predominant source of infant RSVHs and costs.


  • Open Access

    Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990–2015: findings from the Global Burden of Disease 2015 study

    by Ali H. Mokdad, José das Neves, Abdallah Samy, Charbel El Bcheraoui, Haidong Wang, Raghid Charara, Ibrahim Khalil, Maziar Moradi-Lakeh, Ashkan Afshin, Michael Collison, et al.

    Objectives We used the results of the Global Burden of Disease 2015 study to estimate trends of HIV/AIDS burden in Eastern Mediterranean Region (EMR) countries between 1990 and 2015. Methods Tailored estimation methods were used to produce final estimates of mortality. Years of life lost (YLLs) were calculated by multiplying the mortality rate by population by age-specific life expectancy. Years lived with disability (YLDs) were computed as the prevalence of a sequela multiplied by its disability weight. Results In 2015, the rate of HIV/AIDS deaths in the EMR was 1.8 (1.4–2.5) per 100,000 population, a 43% increase from 1990 (0.3; 0.2–0.8). Consequently, the rate of YLLs due to HIV/AIDS increased from 15.3 (7.6–36.2) per 100,000 in 1990 to 81.9 (65.3–114.4) in 2015. The rate of YLDs increased from 1.3 (0.6–3.1) in 1990 to 4.4 (2.7–6.6) in 2015. Conclusions HIV/AIDS morbidity and mortality increased in the EMR since 1990. To reverse this trend and achieve epidemic control, EMR countries should strengthen HIV surveillance, and scale up HIV antiretroviral therapy and comprehensive prevention services.


  • Top Cited Papers
    Open Access

    Child and Adolescent Health From 1990 to 2015

    by The Global Burden of Disease Child, Adolescent Health Collaboration, Nicholas Kassebaum, Hmwe Hmwe Kyu, Leo Zoeckler, Helen Elizabeth Olsen, Katie Thomas, Christine Pinho, Zulfiqar A. Bhutta, Lalit Dandona, et al.

    Reducing mortality among children younger than 5 years has been a focus of significant international attention for several decades, beginning with the Convention on the Rights of the Child, accelerating during the Millennium Development Goal era, and continuing with the Sustainable Development Goals (SDGs).1-3 Global progress in reducing death in children younger than 5 years has been substantial,4 but much less attention has been focused on quantifying and minimizing mortality burden among older children and adolescents.5 Likewise, nonfatal health outcomes have received comparatively little attention despite the fact that injuries, noncommunicable diseases (NCDs), and acquired chronic conditions with childhood onset profoundly affect long-term health trajectories, future health care needs, intellectual development, and economic and productivity prospects.6-8


  • Top Cited Papers
    Open Access

    Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

    by Theo Vos, Christine Allen, Megha Arora, Ryan M Barber, Zulfiqar A Bhutta, Alexandria Brown, Austin Carter, Daniel C Casey, Fiona J Charlson, Alan Z Chen, et al.


  • Top Cited Papers
    Open Access

    Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015

    by Haidong Wang, Tim M Wolock, Austin Carter, Grant Nguyen, Hmwe Hmwe Kyu, Emmanuela Gakidou, Simon I Hay, Edward J Mills, Adam Trickey, William Msemburi, et al.